Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and apatinib combined with local treatment for hepatocellular carcinoma
ChiCTR2100041931Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) and liver cancer, sponsored by Henan Cancer Hospital. Primary endpoints: Progression-free survival, Time to disease progression and 8 more. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ChiCTR2100041931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041931.